ImmunologybioRxiv
Myeloid reprogramming by JAK inhibition enhances checkpoint blockade therapy
J. Zak, I. Pratumchai, B. S. Marro…·J. Teijaro
Ruxolitinib reshapes myeloid immunity to synergize with checkpoint inhibitors, enhancing anti-tumor T cell activity and improving immunotherapy outcomes.
DOI 10.1126/science.ade8520